We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,274

Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


Supreme Court Updates - Intellectual Property Weekly Abstracts - Week of January 16, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Supreme Court of Canada announced that judgment in this application for leave to appeal will be delivered on Thursday, January 19, 2017. The


Dismissed Motion for Interlocutory Injunction Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

This was an appeal against Justice Manson's unreported decision in 2016 FC 606, dismissing TearLab's motion for an interlocutory injunction to prevent


Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The


Patent Validity and Infringement Upheld on Appeal; Limitation Period in Patent Act not Necessarily Applicable to Old Act Patents
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

In this case, the FCA considered an appeal and cross-appeal of a decision relating to omeprazole. The trial decision can be found here (2015 FC 322


Apotex’s Infringement of AstraZeneca’s Omeprazole Formulation Patent Upheld
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 16 2017

The Federal Court of Appeal, in a unanimous decision released on January 12, 2017 (2017 FCA 9), has affirmed the validity of AstraZeneca's Patent No


PAB Finds Proposed Amendments Overcome Defects in Stabilized Alpha Helical Peptides Application
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • January 10 2017

It is difficult to obtain patent protection on an invention if its only described purpose is as an object of study. In this case, the Patent Appeal


Canadian patent law: 2016 year in review
  • Gowling WLG
  • Canada
  • January 4 2017

A wide variety of patent law issues were litigated and decided upon in 2016. For instance, the Supreme Court considered the law of utility, the


FC Rules PM(NOC) Prohibition Application Not An Abuse of Process
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • January 3 2017

The Federal Court (“FC”) has discretion as to whether or not to stay a prohibition application under the Patented Medicines (Notice of Compliance


Prohibition dismissed on the basis of non-infringement
  • Borden Ladner Gervais LLP
  • Canada
  • December 21 2016

The Court dismissed a prohibition application, which would have prevented Pharmascience from coming to market with its PMS-Zolpidem until the '988